Efficacy and Safety of Xacrel ® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis
Conditions: Multiple Sclerosis; Relapsing-Remitting Interventions: Biological: Ocrelizumab (CinnaGen, Iran); Biological: Ocrelizumab (Roche, Switzerland) Sponsor: Cinnagen Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2021 Category: Research Source Type: clinical trials
Effect of curcumin-pipeine supplementation on clinical status, mortality rate, oxidative stress, and inflammatory markers in critically ill ICU patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial
This study aims to investigate the efficacy of curcumin-piperine co-supplementation on oxidative stress factors, clinical symptoms, and mortality rate in patients with coronavirus (COVID-19) admitted to the intensive care unit (ICU).Trial designThis study is a randomized, placebo-controlled, double-blind, parallel-arm clinical trial.ParticipantsThe study participants will be recruited from patients admitted to the ICU of Al-Zahra hospital with a definitive diagnosis of COVID-19. The inclusion criteria are aged between 20 and 75 years, confirmation of COVID-19 based on the PCR test, and admitted to the ICU. The exclusion cr...
Source: Trials - July 6, 2021 Category: Research Source Type: clinical trials
Evaluation of the efficacy and safety of recombinant erythropoietin on the improvement of hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial
This study will be performed at Shahid Mohammadi Hospital in Bandar Abbas, Hormozgan in Iran. All positive (PCR confirmed) COVID-19 patients ≤65 years old who have Hb≤9 and at least one of the severe COVID-19 symptoms (tachypnea (breathing rate> 30 beats per minute), hypoxemia (O2 ≤93 saturation, the partial pressure ratio of arterial oxygen<300), Lung infiltration (> 50% of lung field within 24 to 48 hours), progressive lymphopenia, LDH>245 U/I, CRP>100) and are willing to cooperate in this project will be included in the study. Patients with a history of coronary heart disease, thrombosis, deep vein ...
Source: Trials - July 6, 2021 Category: Research Source Type: clinical trials
Safety and Effectiveness of Cinnomer ® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran
Condition: Relapsing Multiple Sclerosis Intervention: Drug: Glatiramer Acetate Sponsor: Cinnagen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 16, 2021 Category: Research Source Type: clinical trials
